2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- A new study on Cardiovascular Diseases and Conditions is now available. According to news reporting originating in Jacksonville, United States, by NewsRx journalists, research stated, “It is important to understand patients’ experiences of statin-associated adverse effects to potentially identify those at risk for stopping treatment. The goal of the STatin Adverse Treatment Experience survey was to describe patients’ experiences after reporting recent statin-associated adverse event and identify opportunities to improve adherence and outcomes.”
Funders for this research include Amgen Inc., Amgen Inc.
The news reporters obtained a quote from the research from National Lipid Association, “The survey was developed in 3 stages: qualitative item development, pilot evaluation of initial item performance, and quantitative evaluation using a large commercial sample. Respondents with self-reported high cholesterol who had taken a statin in the past 2 years and experienced statin-associated symptom in the past 6 months were included (N = 1500). Mean age was 58 years, 40.3% were men, and 43.2% had tried >= 2 statins. Many had clinical comorbidities associated with increased risk for cardiovascular disease (atherosclerotic cardiovascular disease, 22.5%; diabetes, 25.8%; hypertension, 56.0%). The most important patient-reported reasons for continuing current statin therapy (n = 1168; 77.9%) were avoiding a heart attack or stroke, lowering cholesterol, and doctor recommendation. Being bothered by and not being able to tolerate side effects were the main reasons respondents discontinued statins (n = 332; 22.1%). Respondents who discontinued statins reported significantly higher mean Symptom Severity (10.6 vs 8.7, P<.001) and Impact Severity scores (11.8 vs 9.8, P<.001) compared with those who continued. The STatin Adverse Treatment Experience survey highlights the importance of patients’ adverse experiences with statins and how symptom and impact scores affect decisions to continue or discontinue therapy.”
According to the news reporters, the research concluded: “These data provide a foundation to increase providers’ awareness of statin tolerability from the patient’s perspective and encourage benefit-risk discussions.”
For more information on this research see: The Statin Adverse Treatment Experience Survey: Experience of Patients Reporting Side Effects of Statin Therapy. Journal of Clinical Lipidology, 2019;13(3):415-424. Journal of Clinical Lipidology can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA. (Elsevier - www.elsevier.com; Journal of Clinical Lipidology - http://www.journals.elsevier.com/journal-of-clinical-lipidology/)
Our news correspondents report that additional information may be obtained by contacting T.A. Jacobson, National Lipid Association, Hlth Qual & Res Comm, Jacksonville, FL, United States. Additional authors for this research include M.K. Cheeley, P.H. Jones, R. La Forge, K.C. Maki, J.D. Cohen, J.A.G. Lopez and P. Xiang.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jacl.2019.04.011. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Copyright © 2019 NewsRx LLC, Disease Prevention Daily, source Health Newsletters